Bill Title: Clarifies that product approval from U.S. Food and Drug Administration is not required for drug manufacturer to file registration statement, and specifies timeframe by which DOH must review registration statements.

Spectrum: Slight Partisan Bill (Democrat 7-3)

Status: (Passed) 2016-12-05 - Approved P.L.2016, c.73. [S2024 Detail]

---

Bill Drafts

Revision	Date	Format	Source	View
Chaptered	2016-12-30	HTML/Text	Link	View
Introduced	2016-04-18	HTML/Text	Link	View

Amendments

Amendment	Date	Disposition	Format	Source	View
No bill amendments currently on file for New Jersey S2024

Supplemental Documents

Title	Description	Date	Format	Source	View
No supplemental documents for New Jersey S2024 currently on file.

Social Comments on NJ S2024